CASIF CASI Pharmaceuticals, Inc.

$0.12

CASI Pharmaceuticals, Inc. (CASIF) is expected to report earnings on August 14, 2026, before the market open. The consensus earnings estimate is a loss of $0.35 per share.

Earnings Date
3rd Quarter, Sep 2026
Aug 14
Friday · Before Open
Earnings Whisper
-
vs ($0.35)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.